Phase 1b TRIMM-2 Trial Results for Subcutaneous Talquetamab plus Daratumumab in Patients with RRMM

2021 Year in Review - Multiple Myeloma —February 23, 2022

Categories:

Multiple Myeloma

Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talquetamab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination.

Based on preclinical evidence that the addition of the anti-CD38 monoclonal antibody daratumumab enhanced multiple myeloma (MM) cell killing mediated by the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talquetamab, the combination was evaluated in the phase 1b multicohort study (TRIMM-2; NCT04108195) in patients with relapsed/refractory multiple myeloma (RRMM). Preliminary results of the trial were reported at the 2021 ASH Annual Meeting and summarized here.

The study enrolled patients aged ≥18 years with a diagnosis of MM, who had received ≥3 previous lines of therapy, had previous exposure or were refractory to a proteasome inhibitor and immunomodulatory drug, but had no previous exposure to anti-CD38 therapy in the past 90 days. Eligible patients received daratumumab (1800 mg) plus subcutaneous talquetamab (administered with step-up dosing in 3 cohorts: 400 µg/kg weekly, 400 µg/kg biweekly, 800 µg/kg biweekly) in 28-day cycles. The primary objectives were to identify the recommended phase 2 dose (RP2D) of talquetamab plus daratumumab and to characterize the safety of talquetamab plus daratumumab at the RP2D. The data cutoff date was September 7, 2021.

A total of 29 patients received subcutaneous talquetamab plus daratumumab in 3 separate cohorts: daratumumab 1800 mg plus talquetamab 400 µg/kg weekly (N = 9), daratumumab 1800 mg plus talquetamab 400 µg/kg biweekly (N = 5), and daratumumab 1800 mg plus talquetamab 800 µg/kg biweekly (N = 15). Across the 3 cohorts, the median age was 66 years and 55.2% were female. Patients were heavily pretreated and had received a median of 6 previous lines of therapy; 79.3% were triple-class–exposed (82.6% had received daratumumab before, and 8.7% had received isatuximab before) and 65.5% were penta-drug–exposed. The median follow-up across the 3 cohorts was 2.9 months.

Across the 3 cohorts, any grade adverse events (AEs) were reported in 95.7% of patients; the most common reported AEs that occurred in ≥20% of patients were cytokine release syndrome (CRS; 55.2%), dysgeusia (48.3%), neutropenia (41.4%), thrombocytopenia (34.5%), infections (34.5%), anemia (31.0%), and skin exfoliation (27.6%). Grade 3/4 AEs occurred in 78.3% of patients and included neutropenia (31%), thrombocytopenia (20.7%), anemia (20.7%), and infections (10%). All CRS events were grade 1/2; the median time to CRS onset was 2 days, and the median duration was 2 days. Skin disorders were reported in 65% of patients (grade 3/4: 10.3%), including nail disorders in 31% (all grade 1/2). Two events of immune effector-cell–associated neurotoxicity syndrome were reported; one was a grade 1 event, and another was a grade 3 event, both of which resolved. One death as a result of disease progression was reported in the daratumumab 1800-mg plus talquetamab 400-μg/kg biweekly cohort.

Patients evaluable for efficacy analysis had received ≥1 study treatments and 1 postbaseline response evaluation. In the daratumumab 1800-mg plus talquetamab 400-µg/kg weekly cohort (N = 7), 2 patients achieved a complete response or better. In the daratumumab 1800-mg plus talquetamab 400-µg/kg biweekly cohort (N = 5), 1 patient achieved a complete response or better and 3 patients achieved a very good partial response or better. In the daratumumab 1800-mg plus talquetamab 800-µg/kg biweekly cohort (N = 9), 1 patient achieved a complete response or better, 6 patients achieved a very good partial response or better, and 7 achieved a partial response or better. The median time to first response across the talquetamab plus daratumumab cohorts was 1.0 month (range, 0.9-2.4 months), and median duration of response was not reached. Consistent with the pharmacokinetic profile of talquetamab monotherapy, the talquetamab plus daratumumab combination treatment resulted in proinflammatory cytokine production and T-cell activation.

Findings of the multicohort phase 1 TRIMM-2 trial showed that talquetamab plus daratumumab combination therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination.

Source: Chari A, Hari P, Bahlis NJ, et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(suppl 1):161.

Related Articles
Multiple Myeloma Year in Review Introduction
2022 Year in Review - Multiple Myeloma
This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner.
Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial
2022 Year in Review - Multiple Myeloma
The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.
Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone Induction Followed by Daratumumab Maintenance Achieved Durable Responses in Patients with RRMM and NDMM
2022 Year in Review - Multiple Myeloma
Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country